Cautious Prescribing Needed For Newer Products, Express Scripts Exec Says
This article was originally published in The Pink Sheet Daily
Express Scripts chief medical officer recommends that new drugs be prescribed "only in those situations where there is really a proven clinical advantage." Two-thirds of Express Scripts' covered patients had no identifiable gastrointestinal risk factors, the exec says.
You may also be interested in...
FDA's labeling template calls for Pfizer's Celebrex and other prescription NSAIDs to add "black box" warnings on cardiovascular and gastrointestinal risks. FDA is also requiring a warning on skin reactions. The agency issues a medication guide for all NSAIDs.
Pfizer is characterizing FDA's request for a withdrawal of Bextra as a "marketing suspension"; the company hopes to continue discussions on how valdecoxib could re-enter the market. Increased cardiovascular risk plus a "special risk" of serious skin reactions led FDA to recommend pulling the COX-2 inhibitor.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter